Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F] fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate pancer: multicenter Phase IIb clinical trial

Affiliations

¹ Department of Urology, Toho University Sakura Medical Center, Sakura.
² Department of Diagnostic Radiology, Kitasato University School of Medicine, Sagamihara.
³ Department of Urology, National Cancer Center Hospital, Tokyo.
⁴ Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo.
⁵ Department of Urology, Tokyo Women's Medical University, Tokyo.
⁶ Prostate Center and Division of Urology, Chiba Cancer Center, Chiba.
⁷ Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama.
⁸ Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo.
⁹ Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka.
¹⁰ Clinical Development Department, Nihon Medi-Physics Co., Ltd., Tokyo, Japan.

Published Erratum

Hiroyoshi Suzuki et al. Jpn J Clin Oncol. 2017.

. 2017 Mar 1;47(3):283.

doi: 10.1093/jjco/hyw177.

¹ Department of Urology, Toho University Sakura Medical Center, Sakura.
² Department of Diagnostic Radiology, Kitasato University School of Medicine, Sagamihara.
³ Department of Urology, National Cancer Center Hospital, Tokyo.
⁴ Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo.
⁵ Department of Urology, Tokyo Women's Medical University, Tokyo.
⁶ Prostate Center and Division of Urology, Chiba Cancer Center, Chiba.
⁷ Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama.
⁸ Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo.
⁹ Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka.
¹⁰ Clinical Development Department, Nihon Medi-Physics Co., Ltd., Tokyo, Japan.

No abstract available

Erratum for

Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial.
Suzuki H, Inoue Y, Fujimoto H, Yonese J, Tanabe K, Fukasawa S, Inoue T, Saito S, Ueno M, Otaka A. Suzuki H, et al. Jpn J Clin Oncol. 2016 Feb;46(2):152-62. doi: 10.1093/jjco/hyv181. Epub 2016 Jan 4. Jpn J Clin Oncol. 2016. PMID: 26732384 Clinical Trial.